Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2024-12-10 Regulatory Filings
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
Change of Registered Office
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' header and contains standard regulatory boilerplate language, including references to 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content itself is a very brief announcement (under 5,000 characters) stating a 'Change of Registered Office address'. This type of short, formal corporate update that is distributed via the RNS system is best classified as a general Regulatory Filing, as it does not fit the specific criteria for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Given the source and nature, RNS is the most appropriate category.
2024-12-10 English
Changement de siège social
Regulatory Filings Classification · 95% confidence The document is a short announcement dated December 10, 2024, from Novacyt S.A. The primary subject is a 'Changement de siège social' (Change of registered office address). It provides contact details, an 'About Us' section, and details about its business segments. Since the core content is a specific, non-financial operational update (change of address) and not a comprehensive report (like 10-K, IR, ER), it fits best into the general regulatory announcement category. Given the specific options, this type of administrative/corporate action announcement that doesn't fit into DIRS, DIV, CAP, or MANG is typically classified as a general Regulatory Filing (RNS) or potentially a miscellaneous corporate update. Since there is no specific code for 'Change of Address', RNS serves as the most appropriate fallback for a general regulatory announcement.
2024-12-10 French
Liquidity Agreement and Total Voting Rights
Capital/Financing Update Classification · 99% confidence The document is an official announcement released via RNS (RNS Number : 4773O) on December 2, 2024. The content explicitly details a 'Liquidity Agreement Monthly Update' concerning share purchases and sales by a third party (Invest Securities) on behalf of Novacyt, and it also provides the 'Total Voting Rights' figure. This type of regular, specific operational/shareholder information update, especially when tied to a liquidity agreement and total share count disclosure (often required by listing rules), fits best under the general category of regulatory announcements that are not a full financial report (10-K, IR) or a specific insider trade report (DIRS). Since it is a formal, periodic disclosure disseminated through the RNS system, and it doesn't fit the more specific categories like DIV, DIRS, or ER, the most appropriate classification is the general regulatory filing category, RNS.
2024-12-02 English
Liquidity Agreement and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is titled "Liquidity Agreement Monthly Update and Total Voting Rights". It explicitly details the transactions (purchases and sales of ordinary shares) conducted by the liquidity provider (Invest Securities) under the Liquidity Agreement for the period of November 1 to November 30, 2024. It also provides the total number of ordinary shares and total voting rights as of November 30, 2024. This content directly relates to the company's share structure, treasury stock management, and compliance with voting rights disclosure rules, which is a specific type of regulatory or corporate action announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). The closest fit among the provided codes is related to share capital changes or regulatory disclosures. Since it specifically reports on the status of treasury shares resulting from a share repurchase/liquidity agreement and provides the total voting rights denominator, it strongly aligns with announcements concerning share capital or transactions in own shares. However, the primary focus is the monthly update on the liquidity agreement and the total voting rights calculation, which is a mandatory disclosure often falling under general regulatory announcements or share-related updates. Given the options, 'Transaction in Own Shares' (POS) covers the share repurchase aspect, but 'Total Voting Rights' is a distinct regulatory disclosure. Since the document is a formal, periodic update concerning share transactions (repurchases/treasury stock) and voting rights, it fits best under the category related to share transactions (POS) or potentially a general regulatory filing (RNS). Because the core activity described is the execution of a share repurchase program (buying and selling shares under the agreement, resulting in treasury shares), POS is a strong candidate. However, the inclusion of 'Total Voting Rights' (which is a specific disclosure often required alongside share changes) suggests a broader regulatory filing. Reviewing the definitions, 'POS' is for 'Report of the company buying back or selling its own shares'. This document reports on the *activity* under the agreement that results in treasury shares. 'RNS' is the fallback. Given the specific nature of reporting on treasury share movements and voting rights, and lacking a specific 'Share Transaction Report' code, I will classify it based on the most prominent activity: the share repurchase/treasury management, which is POS. If POS is too narrow, RNS would be the fallback. Let's re-evaluate: The document is a formal announcement detailing the monthly activity under a share repurchase/liquidity agreement and the resulting total voting rights. This is a specific type of corporate action disclosure. Since the activity directly involves the company's own shares being bought/sold under an agreement to manage liquidity/treasury, POS is the most specific fit for the core activity described, even though it also contains voting rights information. I will assign POS with high confidence as it details the mechanics and results of the share transaction program.
2024-12-02 English
Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote" (Monthly information on the liquidity contract and on the total number of voting rights). It details the monthly activity (purchases and sales of shares) under a liquidity contract (share buyback/stabilization program) for the period November 1 to November 30, 2024, and reports the total number of voting rights. This activity directly relates to the company managing its own shares, which falls under the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV). Since it specifically reports on the company's transactions in its own shares, POS is the most accurate classification.
2024-12-02 French
Further expansion of cost reduction programme
Earnings Release Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date (14 November 2024) and company information (Novacyt S.A.). The content discusses operational changes, cost reduction programs, and facility consolidations, which are material corporate updates. Crucially, the document ends with the standard disclaimer: "This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom." This strongly indicates it is a regulatory news service announcement. Since the content is a specific operational update (cost savings, site closure consultation) and not a full financial report (10-K, IR), dividend notice (DIV), or earnings release (ER), it fits best under the general regulatory announcement category, RNS, which serves as the fallback for specific announcements not covered elsewhere. FY 2024
2024-11-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.